nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS1—Ifosfamide—testicular cancer	0.15	0.299	CbGbCtD
Sulindac—PTGS2—Cisplatin—testicular cancer	0.0862	0.172	CbGbCtD
Sulindac—PTGS2—Etoposide—testicular cancer	0.0847	0.169	CbGbCtD
Sulindac—PTGS1—Etoposide—testicular cancer	0.0715	0.143	CbGbCtD
Sulindac—SLC22A6—Methotrexate—testicular cancer	0.0414	0.0828	CbGbCtD
Sulindac—ALB—Methotrexate—testicular cancer	0.0353	0.0705	CbGbCtD
Sulindac—CYP1A2—Etoposide—testicular cancer	0.0319	0.0638	CbGbCtD
Sulindac—AKR1B1—embryo—testicular cancer	0.00977	0.105	CbGeAlD
Sulindac—AKR1B1—seminal vesicle—testicular cancer	0.00918	0.0988	CbGeAlD
Sulindac—MAPK3—embryo—testicular cancer	0.00708	0.0762	CbGeAlD
Sulindac—MAPK3—seminal vesicle—testicular cancer	0.00665	0.0716	CbGeAlD
Sulindac—AKR1B1—gonad—testicular cancer	0.00663	0.0714	CbGeAlD
Sulindac—AKR1B1—female gonad—testicular cancer	0.00539	0.058	CbGeAlD
Sulindac—MAPK3—gonad—testicular cancer	0.00481	0.0517	CbGeAlD
Sulindac—AKR1B1—testis—testicular cancer	0.00478	0.0514	CbGeAlD
Sulindac—PPARD—Ectoderm Differentiation—TFAP2C—testicular cancer	0.00475	0.0457	CbGpPWpGaD
Sulindac—PPARD—female gonad—testicular cancer	0.00424	0.0456	CbGeAlD
Sulindac—PPARD—NRF2 pathway—SLC2A6—testicular cancer	0.00415	0.04	CbGpPWpGaD
Sulindac—MAPK3—female gonad—testicular cancer	0.00391	0.042	CbGeAlD
Sulindac—PPARD—testis—testicular cancer	0.00376	0.0405	CbGeAlD
Sulindac—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.00376	0.0362	CbGpPWpGaD
Sulindac—MAPK3—testis—testicular cancer	0.00347	0.0373	CbGeAlD
Sulindac—AKR1B1—lymph node—testicular cancer	0.00346	0.0373	CbGeAlD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00332	0.032	CbGpPWpGaD
Sulindac—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.00298	0.0288	CbGpPWpGaD
Sulindac—PPARD—lymph node—testicular cancer	0.00272	0.0293	CbGeAlD
Sulindac—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00272	0.0262	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—INSL3—testicular cancer	0.00253	0.0244	CbGpPWpGaD
Sulindac—MAPK3—lymph node—testicular cancer	0.00251	0.027	CbGeAlD
Sulindac—PTGS2—embryo—testicular cancer	0.00184	0.0198	CbGeAlD
Sulindac—PTGS1—seminal vesicle—testicular cancer	0.00181	0.0195	CbGeAlD
Sulindac—PTGS2—seminal vesicle—testicular cancer	0.00173	0.0186	CbGeAlD
Sulindac—ALB—testis—testicular cancer	0.00165	0.0178	CbGeAlD
Sulindac—MAPK3—BCR signaling pathway—BCL10—testicular cancer	0.0016	0.0154	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—INSL3—testicular cancer	0.00143	0.0138	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.0014	0.0135	CbGpPWpGaD
Sulindac—PTGS1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00136	0.0131	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—INSL3—testicular cancer	0.0013	0.0125	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—BCL10—testicular cancer	0.00126	0.0122	CbGpPWpGaD
Sulindac—SLC22A6—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00124	0.0119	CbGpPWpGaD
Sulindac—CYP1A1—female gonad—testicular cancer	0.00121	0.013	CbGeAlD
Sulindac—MAPK3—Signaling events mediated by Stem cell factor receptor (c-Kit)—KITLG—testicular cancer	0.0012	0.0116	CbGpPWpGaD
Sulindac—ALB—lymph node—testicular cancer	0.0012	0.0129	CbGeAlD
Sulindac—MAPK3—Syndecan-2-mediated signaling events—FGFR3—testicular cancer	0.00118	0.0114	CbGpPWpGaD
Sulindac—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00115	0.0111	CbGpPWpGaD
Sulindac—MAPK3—RNA Polymerase I Promoter Opening—H2AFZ—testicular cancer	0.00114	0.011	CbGpPWpGaD
Sulindac—MAPK3—Syndecan-1-mediated signaling events—FGFR3—testicular cancer	0.00113	0.0109	CbGpPWpGaD
Sulindac—MAPK3—Negative regulation of FGFR signaling—FGFR3—testicular cancer	0.00108	0.0104	CbGpPWpGaD
Sulindac—MAPK3—Osteopontin-mediated events—MMP2—testicular cancer	0.00108	0.0104	CbGpPWpGaD
Sulindac—PTGS2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00108	0.0104	CbGpPWpGaD
Sulindac—MAPK3—Kit receptor signaling pathway—KITLG—testicular cancer	0.00107	0.0103	CbGpPWpGaD
Sulindac—PTGS1—female gonad—testicular cancer	0.00106	0.0114	CbGeAlD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00102	0.00985	CbGpPWpGaD
Sulindac—PTGS2—female gonad—testicular cancer	0.00101	0.0109	CbGeAlD
Sulindac—MAPK3—FRS2-mediated cascade—FGFR3—testicular cancer	0.001	0.00967	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—PRDM14—testicular cancer	0.00098	0.00945	CbGpPWpGaD
Sulindac—MAPK3—Syndecan-2-mediated signaling events—MMP2—testicular cancer	0.000958	0.00923	CbGpPWpGaD
Sulindac—CYP1A1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000956	0.00922	CbGpPWpGaD
Sulindac—PTGS1—testis—testicular cancer	0.000942	0.0101	CbGeAlD
Sulindac—MAPK3—IRS-mediated signalling—STK11—testicular cancer	0.000861	0.0083	CbGpPWpGaD
Sulindac—MAPK3—FGF signaling pathway—FGFR3—testicular cancer	0.000851	0.00821	CbGpPWpGaD
Sulindac—MAPK3—IRS-related events—STK11—testicular cancer	0.000838	0.00807	CbGpPWpGaD
Sulindac—MAPK3—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.00083	0.008	CbGpPWpGaD
Sulindac—MAPK3—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—testicular cancer	0.000818	0.00789	CbGpPWpGaD
Sulindac—MAPK3—IGF1R signaling cascade—STK11—testicular cancer	0.000808	0.00779	CbGpPWpGaD
Sulindac—MAPK3—Insulin receptor signalling cascade—STK11—testicular cancer	0.000808	0.00779	CbGpPWpGaD
Sulindac—CYP1A1—lymph node—testicular cancer	0.000777	0.00836	CbGeAlD
Sulindac—PTGDR2—Signaling Pathways—INSL3—testicular cancer	0.000767	0.0074	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—MAD1L1—testicular cancer	0.000746	0.00719	CbGpPWpGaD
Sulindac—MAPK3—Angiopoietin receptor Tie2-mediated signaling—MMP2—testicular cancer	0.000737	0.0071	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.000735	0.00708	CbGpPWpGaD
Sulindac—MAPK3—Senescence-Associated Secretory Phenotype (SASP)—H2AFZ—testicular cancer	0.000732	0.00705	CbGpPWpGaD
Sulindac—MAPK3—RNA Polymerase I Promoter Clearance—H2AFZ—testicular cancer	0.000732	0.00705	CbGpPWpGaD
Sulindac—MAPK3—Kit receptor signaling pathway—KIT—testicular cancer	0.000728	0.00702	CbGpPWpGaD
Sulindac—MAPK3—RNA Polymerase I Transcription—H2AFZ—testicular cancer	0.000721	0.00694	CbGpPWpGaD
Sulindac—PTGS1—lymph node—testicular cancer	0.000683	0.00735	CbGeAlD
Sulindac—MAPK3—Signaling by Insulin receptor—STK11—testicular cancer	0.000672	0.00647	CbGpPWpGaD
Sulindac—MAPK3—Oxidative Stress Induced Senescence—H2AFZ—testicular cancer	0.000662	0.00638	CbGpPWpGaD
Sulindac—PTGS2—lymph node—testicular cancer	0.000652	0.00702	CbGeAlD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000652	0.00628	CbGpPWpGaD
Sulindac—MAPK3—ATF-2 transcription factor network—MMP2—testicular cancer	0.000645	0.00622	CbGpPWpGaD
Sulindac—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000642	0.00619	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000628	0.00605	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—HPGDS—testicular cancer	0.000624	0.00601	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00062	0.00598	CbGpPWpGaD
Sulindac—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00061	0.00588	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—DNMT3L—testicular cancer	0.000607	0.00585	CbGpPWpGaD
Sulindac—MAPK3—Mitotic Prophase—H2AFZ—testicular cancer	0.000595	0.00573	CbGpPWpGaD
Sulindac—MAPK3—IRS-mediated signalling—FGFR3—testicular cancer	0.000592	0.00571	CbGpPWpGaD
Sulindac—MAPK3—AGE/RAGE pathway—MMP2—testicular cancer	0.00059	0.00569	CbGpPWpGaD
Sulindac—MAPK3—IRS-related events—FGFR3—testicular cancer	0.000576	0.00555	CbGpPWpGaD
Sulindac—MAPK3—RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription—H2AFZ—testicular cancer	0.000575	0.00554	CbGpPWpGaD
Sulindac—MAPK3—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.000571	0.0055	CbGpPWpGaD
Sulindac—MAPK3—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.000556	0.00536	CbGpPWpGaD
Sulindac—MAPK3—IGF1R signaling cascade—FGFR3—testicular cancer	0.000556	0.00536	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—KITLG—testicular cancer	0.000532	0.00512	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—H2AFZ—testicular cancer	0.00052	0.00501	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000509	0.0049	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000507	0.00489	CbGpPWpGaD
Sulindac—PTGS1—Biological oxidations—HPGDS—testicular cancer	0.000505	0.00487	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—KITLG—testicular cancer	0.000501	0.00482	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—KITLG—testicular cancer	0.000478	0.00461	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—KITLG—testicular cancer	0.000478	0.00461	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—KITLG—testicular cancer	0.000476	0.00458	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—KITLG—testicular cancer	0.000473	0.00456	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—KITLG—testicular cancer	0.000471	0.00454	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—H2AFZ—testicular cancer	0.000463	0.00446	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000462	0.00445	CbGpPWpGaD
Sulindac—MAPK3—M Phase—MAD1L1—testicular cancer	0.000459	0.00443	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—STK11—testicular cancer	0.000453	0.00437	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000451	0.00434	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—KITLG—testicular cancer	0.000443	0.00427	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000443	0.00427	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—KITLG—testicular cancer	0.000443	0.00427	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—KITLG—testicular cancer	0.000439	0.00423	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000435	0.0042	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—KITLG—testicular cancer	0.000433	0.00418	CbGpPWpGaD
Sulindac—MAPK3—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.000421	0.00406	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000395	0.00381	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000393	0.00378	CbGpPWpGaD
Sulindac—MAPK3—Transcription—H2AFZ—testicular cancer	0.000389	0.00375	CbGpPWpGaD
Sulindac—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	0.000388	0.00374	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000378	0.00364	CbGpPWpGaD
Sulindac—MAPK3—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000378	0.00364	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—INSL3—testicular cancer	0.000373	0.00359	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—FGFR3—testicular cancer	0.000372	0.00359	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000369	0.00356	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—KIT—testicular cancer	0.000363	0.0035	CbGpPWpGaD
Sulindac—CYP1A1—Biological oxidations—HPGDS—testicular cancer	0.000356	0.00343	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—FGFR3—testicular cancer	0.000355	0.00342	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—FGFR3—testicular cancer	0.000354	0.00341	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—FGFR3—testicular cancer	0.000352	0.00339	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—FGFR3—testicular cancer	0.00035	0.00337	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—H2AFZ—testicular cancer	0.00035	0.00337	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000347	0.00335	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—KIT—testicular cancer	0.000342	0.00329	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000329	0.00317	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000329	0.00317	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—FGFR3—testicular cancer	0.000329	0.00317	CbGpPWpGaD
Sulindac—Pancytopenia—Epirubicin—testicular cancer	0.000327	0.00108	CcSEcCtD
Sulindac—PTGS2—C-MYB transcription factor network—KIT—testicular cancer	0.000326	0.00315	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000326	0.00315	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—FGFR3—testicular cancer	0.000326	0.00315	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—KIT—testicular cancer	0.000326	0.00314	CbGpPWpGaD
Sulindac—Hypotension—Etoposide—testicular cancer	0.000326	0.00108	CcSEcCtD
Sulindac—Rash—Bleomycin—testicular cancer	0.000326	0.00108	CcSEcCtD
Sulindac—Gastritis—Doxorubicin—testicular cancer	0.000326	0.00108	CcSEcCtD
Sulindac—Dermatitis—Bleomycin—testicular cancer	0.000326	0.00108	CcSEcCtD
Sulindac—Hypersensitivity—Ifosfamide—testicular cancer	0.000326	0.00108	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000325	0.00107	CcSEcCtD
Sulindac—Muscular weakness—Doxorubicin—testicular cancer	0.000325	0.00107	CcSEcCtD
Sulindac—MAPK3—Signaling by FGFR—KIT—testicular cancer	0.000325	0.00313	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000324	0.00312	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—KIT—testicular cancer	0.000323	0.00311	CbGpPWpGaD
Sulindac—Renal failure—Methotrexate—testicular cancer	0.000322	0.00106	CcSEcCtD
Sulindac—MAPK3—Signaling by PDGF—FGFR3—testicular cancer	0.000322	0.0031	CbGpPWpGaD
Sulindac—Neutropenia—Epirubicin—testicular cancer	0.000322	0.00106	CcSEcCtD
Sulindac—Dysuria—Epirubicin—testicular cancer	0.000322	0.00106	CcSEcCtD
Sulindac—MAPK3—DAP12 signaling—KIT—testicular cancer	0.000321	0.0031	CbGpPWpGaD
Sulindac—MAPK3—M Phase—H2AFZ—testicular cancer	0.00032	0.00309	CbGpPWpGaD
Sulindac—Stomatitis—Methotrexate—testicular cancer	0.00032	0.00106	CcSEcCtD
Sulindac—Conjunctivitis—Methotrexate—testicular cancer	0.000319	0.00105	CcSEcCtD
Sulindac—Asthenia—Ifosfamide—testicular cancer	0.000317	0.00105	CcSEcCtD
Sulindac—Eosinophilia—Doxorubicin—testicular cancer	0.000315	0.00104	CcSEcCtD
Sulindac—MAPK3—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000315	0.00303	CbGpPWpGaD
Sulindac—Sweating—Methotrexate—testicular cancer	0.000314	0.00104	CcSEcCtD
Sulindac—Photosensitivity reaction—Epirubicin—testicular cancer	0.000314	0.00104	CcSEcCtD
Sulindac—Feeling abnormal—Cisplatin—testicular cancer	0.000314	0.00104	CcSEcCtD
Sulindac—Paraesthesia—Etoposide—testicular cancer	0.000313	0.00103	CcSEcCtD
Sulindac—Pruritus—Ifosfamide—testicular cancer	0.000313	0.00103	CcSEcCtD
Sulindac—Haematuria—Methotrexate—testicular cancer	0.000313	0.00103	CcSEcCtD
Sulindac—Pancreatitis—Doxorubicin—testicular cancer	0.000312	0.00103	CcSEcCtD
Sulindac—Dyspnoea—Etoposide—testicular cancer	0.000311	0.00103	CcSEcCtD
Sulindac—Hyperglycaemia—Epirubicin—testicular cancer	0.00031	0.00102	CcSEcCtD
Sulindac—Somnolence—Etoposide—testicular cancer	0.00031	0.00102	CcSEcCtD
Sulindac—MAPK3—Gene Expression—DNMT3L—testicular cancer	0.00031	0.00299	CbGpPWpGaD
Sulindac—Epistaxis—Methotrexate—testicular cancer	0.000309	0.00102	CcSEcCtD
Sulindac—Pneumonia—Epirubicin—testicular cancer	0.000309	0.00102	CcSEcCtD
Sulindac—Nausea—Bleomycin—testicular cancer	0.000307	0.00101	CcSEcCtD
Sulindac—Vomiting—Dactinomycin—testicular cancer	0.000307	0.00101	CcSEcCtD
Sulindac—Agranulocytosis—Methotrexate—testicular cancer	0.000306	0.00101	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000304	0.001	CcSEcCtD
Sulindac—Rash—Dactinomycin—testicular cancer	0.000304	0.001	CcSEcCtD
Sulindac—Decreased appetite—Etoposide—testicular cancer	0.000303	0.001	CcSEcCtD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000302	0.00291	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—KIT—testicular cancer	0.000302	0.00291	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—KIT—testicular cancer	0.000302	0.00291	CbGpPWpGaD
Sulindac—Diarrhoea—Ifosfamide—testicular cancer	0.000302	0.000998	CcSEcCtD
Sulindac—Pancytopenia—Doxorubicin—testicular cancer	0.000302	0.000998	CcSEcCtD
Sulindac—MAPK3—Signaling by NGF—KITLG—testicular cancer	0.000302	0.00291	CbGpPWpGaD
Sulindac—Renal failure—Epirubicin—testicular cancer	0.000302	0.000996	CcSEcCtD
Sulindac—Body temperature increased—Cisplatin—testicular cancer	0.000301	0.000995	CcSEcCtD
Sulindac—Fatigue—Etoposide—testicular cancer	0.000301	0.000994	CcSEcCtD
Sulindac—Neuropathy peripheral—Epirubicin—testicular cancer	0.000301	0.000993	CcSEcCtD
Sulindac—MAPK3—Signaling by EGFR—KIT—testicular cancer	0.0003	0.00289	CbGpPWpGaD
Sulindac—Jaundice—Epirubicin—testicular cancer	0.000299	0.000987	CcSEcCtD
Sulindac—Stomatitis—Epirubicin—testicular cancer	0.000299	0.000987	CcSEcCtD
Sulindac—Constipation—Etoposide—testicular cancer	0.000298	0.000986	CcSEcCtD
Sulindac—Conjunctivitis—Epirubicin—testicular cancer	0.000298	0.000985	CcSEcCtD
Sulindac—Dysuria—Doxorubicin—testicular cancer	0.000298	0.000983	CcSEcCtD
Sulindac—Neutropenia—Doxorubicin—testicular cancer	0.000298	0.000983	CcSEcCtD
Sulindac—MAPK3—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000297	0.00286	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—KIT—testicular cancer	0.000296	0.00285	CbGpPWpGaD
Sulindac—Hepatitis—Methotrexate—testicular cancer	0.000294	0.000972	CcSEcCtD
Sulindac—Sweating—Epirubicin—testicular cancer	0.000294	0.000971	CcSEcCtD
Sulindac—MAPK3—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000293	0.00283	CbGpPWpGaD
Sulindac—Haematuria—Epirubicin—testicular cancer	0.000292	0.000966	CcSEcCtD
Sulindac—Dizziness—Ifosfamide—testicular cancer	0.000292	0.000965	CcSEcCtD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000292	0.00281	CbGpPWpGaD
Sulindac—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000291	0.00096	CcSEcCtD
Sulindac—Epistaxis—Epirubicin—testicular cancer	0.000289	0.000955	CcSEcCtD
Sulindac—Feeling abnormal—Etoposide—testicular cancer	0.000288	0.00095	CcSEcCtD
Sulindac—Hyperglycaemia—Doxorubicin—testicular cancer	0.000287	0.000948	CcSEcCtD
Sulindac—Nausea—Dactinomycin—testicular cancer	0.000286	0.000946	CcSEcCtD
Sulindac—Agranulocytosis—Epirubicin—testicular cancer	0.000286	0.000945	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—BCL10—testicular cancer	0.000286	0.00275	CbGpPWpGaD
Sulindac—Pneumonia—Doxorubicin—testicular cancer	0.000285	0.000943	CcSEcCtD
Sulindac—Gastrointestinal pain—Etoposide—testicular cancer	0.000285	0.000942	CcSEcCtD
Sulindac—Visual impairment—Methotrexate—testicular cancer	0.000284	0.000936	CcSEcCtD
Sulindac—MAPK3—Cell Cycle—MAD1L1—testicular cancer	0.000281	0.00271	CbGpPWpGaD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000281	0.000929	CcSEcCtD
Sulindac—Vomiting—Ifosfamide—testicular cancer	0.000281	0.000928	CcSEcCtD
Sulindac—Hypersensitivity—Cisplatin—testicular cancer	0.000281	0.000927	CcSEcCtD
Sulindac—Renal failure—Doxorubicin—testicular cancer	0.000279	0.000921	CcSEcCtD
Sulindac—Rash—Ifosfamide—testicular cancer	0.000279	0.00092	CcSEcCtD
Sulindac—Dermatitis—Ifosfamide—testicular cancer	0.000278	0.000919	CcSEcCtD
Sulindac—Erythema multiforme—Methotrexate—testicular cancer	0.000278	0.000919	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000278	0.000919	CcSEcCtD
Sulindac—Urticaria—Etoposide—testicular cancer	0.000277	0.000916	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—testicular cancer	0.000277	0.000914	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—testicular cancer	0.000277	0.000914	CcSEcCtD
Sulindac—Body temperature increased—Etoposide—testicular cancer	0.000276	0.000911	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—testicular cancer	0.000276	0.000911	CcSEcCtD
Sulindac—Hepatitis—Epirubicin—testicular cancer	0.000275	0.000909	CcSEcCtD
Sulindac—Tinnitus—Methotrexate—testicular cancer	0.000274	0.000906	CcSEcCtD
Sulindac—Asthenia—Cisplatin—testicular cancer	0.000273	0.000903	CcSEcCtD
Sulindac—Sweating—Doxorubicin—testicular cancer	0.000272	0.000899	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—testicular cancer	0.000271	0.000894	CcSEcCtD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000268	0.00258	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000268	0.00258	CbGpPWpGaD
Sulindac—Epistaxis—Doxorubicin—testicular cancer	0.000268	0.000884	CcSEcCtD
Sulindac—Visual impairment—Epirubicin—testicular cancer	0.000265	0.000876	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—testicular cancer	0.000265	0.000875	CcSEcCtD
Sulindac—Chills—Methotrexate—testicular cancer	0.000264	0.000872	CcSEcCtD
Sulindac—Nausea—Ifosfamide—testicular cancer	0.000262	0.000867	CcSEcCtD
Sulindac—Diarrhoea—Cisplatin—testicular cancer	0.000261	0.000861	CcSEcCtD
Sulindac—Erythema multiforme—Epirubicin—testicular cancer	0.00026	0.00086	CcSEcCtD
Sulindac—Alopecia—Methotrexate—testicular cancer	0.00026	0.000859	CcSEcCtD
Sulindac—Hypersensitivity—Etoposide—testicular cancer	0.000257	0.000849	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—testicular cancer	0.000257	0.000848	CcSEcCtD
Sulindac—Flushing—Epirubicin—testicular cancer	0.000256	0.000844	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—testicular cancer	0.000255	0.000841	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—testicular cancer	0.000251	0.000828	CcSEcCtD
Sulindac—Asthenia—Etoposide—testicular cancer	0.00025	0.000827	CcSEcCtD
Sulindac—Chills—Epirubicin—testicular cancer	0.000247	0.000816	CcSEcCtD
Sulindac—Pruritus—Etoposide—testicular cancer	0.000247	0.000815	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—testicular cancer	0.000246	0.000812	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—H2AFZ—testicular cancer	0.000246	0.00237	CbGpPWpGaD
Sulindac—Visual impairment—Doxorubicin—testicular cancer	0.000246	0.000811	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—STK11—testicular cancer	0.000244	0.00235	CbGpPWpGaD
Sulindac—Alopecia—Epirubicin—testicular cancer	0.000243	0.000804	CcSEcCtD
Sulindac—Vomiting—Cisplatin—testicular cancer	0.000242	0.0008	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—testicular cancer	0.000241	0.000797	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—testicular cancer	0.000241	0.000796	CcSEcCtD
Sulindac—Rash—Cisplatin—testicular cancer	0.00024	0.000793	CcSEcCtD
Sulindac—Dermatitis—Cisplatin—testicular cancer	0.00024	0.000793	CcSEcCtD
Sulindac—Diarrhoea—Etoposide—testicular cancer	0.000239	0.000789	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—testicular cancer	0.000238	0.000785	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—testicular cancer	0.000238	0.000785	CcSEcCtD
Sulindac—Anaemia—Methotrexate—testicular cancer	0.000237	0.000782	CcSEcCtD
Sulindac—Flushing—Doxorubicin—testicular cancer	0.000236	0.000781	CcSEcCtD
Sulindac—Flatulence—Epirubicin—testicular cancer	0.000236	0.00078	CcSEcCtD
Sulindac—Tension—Epirubicin—testicular cancer	0.000235	0.000777	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—testicular cancer	0.000235	0.000775	CcSEcCtD
Sulindac—Nervousness—Epirubicin—testicular cancer	0.000233	0.000769	CcSEcCtD
Sulindac—Malaise—Methotrexate—testicular cancer	0.000231	0.000763	CcSEcCtD
Sulindac—Dizziness—Etoposide—testicular cancer	0.000231	0.000762	CcSEcCtD
Sulindac—Vertigo—Methotrexate—testicular cancer	0.00023	0.00076	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—testicular cancer	0.000229	0.000757	CcSEcCtD
Sulindac—Chills—Doxorubicin—testicular cancer	0.000229	0.000755	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—testicular cancer	0.000228	0.000752	CcSEcCtD
Sulindac—CYP1A2—Biological oxidations—HPGDS—testicular cancer	0.000227	0.00219	CbGpPWpGaD
Sulindac—Nausea—Cisplatin—testicular cancer	0.000226	0.000747	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—KITLG—testicular cancer	0.000226	0.00218	CbGpPWpGaD
Sulindac—Vision blurred—Epirubicin—testicular cancer	0.000226	0.000746	CcSEcCtD
Sulindac—PPARD—Metabolism—HPGDS—testicular cancer	0.000226	0.00218	CbGpPWpGaD
Sulindac—Alopecia—Doxorubicin—testicular cancer	0.000225	0.000744	CcSEcCtD
Sulindac—MAPK3—Signaling by NGF—FGFR3—testicular cancer	0.000224	0.00216	CbGpPWpGaD
Sulindac—Ill-defined disorder—Epirubicin—testicular cancer	0.000222	0.000735	CcSEcCtD
Sulindac—Convulsion—Methotrexate—testicular cancer	0.000222	0.000733	CcSEcCtD
Sulindac—Vomiting—Etoposide—testicular cancer	0.000222	0.000733	CcSEcCtD
Sulindac—Anaemia—Epirubicin—testicular cancer	0.000222	0.000732	CcSEcCtD
Sulindac—MAPK3—Signaling Pathways—INSL3—testicular cancer	0.00022	0.00212	CbGpPWpGaD
Sulindac—Rash—Etoposide—testicular cancer	0.00022	0.000727	CcSEcCtD
Sulindac—Dermatitis—Etoposide—testicular cancer	0.00022	0.000726	CcSEcCtD
Sulindac—MAPK3—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000219	0.00211	CbGpPWpGaD
Sulindac—Headache—Etoposide—testicular cancer	0.000219	0.000722	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—testicular cancer	0.000219	0.000722	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—testicular cancer	0.000218	0.00072	CcSEcCtD
Sulindac—Chest pain—Methotrexate—testicular cancer	0.000218	0.00072	CcSEcCtD
Sulindac—Myalgia—Methotrexate—testicular cancer	0.000218	0.00072	CcSEcCtD
Sulindac—Tension—Doxorubicin—testicular cancer	0.000218	0.000719	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—testicular cancer	0.000217	0.000717	CcSEcCtD
Sulindac—Malaise—Epirubicin—testicular cancer	0.000216	0.000714	CcSEcCtD
Sulindac—Discomfort—Methotrexate—testicular cancer	0.000215	0.000712	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—testicular cancer	0.000215	0.000711	CcSEcCtD
Sulindac—Vertigo—Epirubicin—testicular cancer	0.000215	0.000711	CcSEcCtD
Sulindac—Syncope—Epirubicin—testicular cancer	0.000215	0.00071	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—testicular cancer	0.000215	0.000709	CcSEcCtD
Sulindac—PPARD—Gene Expression—H2AFZ—testicular cancer	0.000212	0.00205	CbGpPWpGaD
Sulindac—Palpitations—Epirubicin—testicular cancer	0.000212	0.0007	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—testicular cancer	0.000211	0.000696	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—testicular cancer	0.000209	0.00069	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—testicular cancer	0.000209	0.00069	CcSEcCtD
Sulindac—Convulsion—Epirubicin—testicular cancer	0.000208	0.000686	CcSEcCtD
Sulindac—Nausea—Etoposide—testicular cancer	0.000207	0.000685	CcSEcCtD
Sulindac—Hypertension—Epirubicin—testicular cancer	0.000207	0.000683	CcSEcCtD
Sulindac—MAPK3—Signaling by NGF—KIT—testicular cancer	0.000206	0.00199	CbGpPWpGaD
Sulindac—Ill-defined disorder—Doxorubicin—testicular cancer	0.000206	0.00068	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—testicular cancer	0.000205	0.000677	CcSEcCtD
Sulindac—Thrombocytopenia—Methotrexate—testicular cancer	0.000205	0.000676	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—testicular cancer	0.000204	0.000674	CcSEcCtD
Sulindac—Chest pain—Epirubicin—testicular cancer	0.000204	0.000674	CcSEcCtD
Sulindac—Myalgia—Epirubicin—testicular cancer	0.000204	0.000674	CcSEcCtD
Sulindac—Hyperhidrosis—Methotrexate—testicular cancer	0.000202	0.000667	CcSEcCtD
Sulindac—Discomfort—Epirubicin—testicular cancer	0.000202	0.000666	CcSEcCtD
Sulindac—Malaise—Doxorubicin—testicular cancer	0.0002	0.000661	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—testicular cancer	0.000199	0.000658	CcSEcCtD
Sulindac—Anorexia—Methotrexate—testicular cancer	0.000199	0.000658	CcSEcCtD
Sulindac—Syncope—Doxorubicin—testicular cancer	0.000199	0.000657	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—testicular cancer	0.000199	0.000656	CcSEcCtD
Sulindac—MAPK3—Cell Cycle—H2AFZ—testicular cancer	0.000196	0.00189	CbGpPWpGaD
Sulindac—Palpitations—Doxorubicin—testicular cancer	0.000196	0.000647	CcSEcCtD
Sulindac—Oedema—Epirubicin—testicular cancer	0.000196	0.000646	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—testicular cancer	0.000196	0.000646	CcSEcCtD
Sulindac—Hypotension—Methotrexate—testicular cancer	0.000195	0.000645	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—testicular cancer	0.000195	0.000644	CcSEcCtD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000194	0.00187	CbGpPWpGaD
Sulindac—Shock—Epirubicin—testicular cancer	0.000192	0.000636	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—testicular cancer	0.000192	0.000635	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—testicular cancer	0.000192	0.000633	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—testicular cancer	0.000192	0.000632	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—testicular cancer	0.000191	0.000631	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00019	0.000629	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—testicular cancer	0.000189	0.000625	CcSEcCtD
Sulindac—Insomnia—Methotrexate—testicular cancer	0.000189	0.000624	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—testicular cancer	0.000189	0.000624	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—testicular cancer	0.000189	0.000624	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—testicular cancer	0.000189	0.000624	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—testicular cancer	0.000188	0.00062	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—testicular cancer	0.000187	0.000616	CcSEcCtD
Sulindac—Anorexia—Epirubicin—testicular cancer	0.000186	0.000616	CcSEcCtD
Sulindac—Dyspnoea—Methotrexate—testicular cancer	0.000186	0.000615	CcSEcCtD
Sulindac—Somnolence—Methotrexate—testicular cancer	0.000186	0.000614	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—testicular cancer	0.000184	0.000608	CcSEcCtD
Sulindac—Hypotension—Epirubicin—testicular cancer	0.000183	0.000604	CcSEcCtD
Sulindac—Decreased appetite—Methotrexate—testicular cancer	0.000182	0.0006	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—testicular cancer	0.000181	0.000598	CcSEcCtD
Sulindac—Oedema—Doxorubicin—testicular cancer	0.000181	0.000598	CcSEcCtD
Sulindac—Fatigue—Methotrexate—testicular cancer	0.00018	0.000595	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000178	0.000589	CcSEcCtD
Sulindac—Shock—Doxorubicin—testicular cancer	0.000178	0.000588	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—testicular cancer	0.000177	0.000585	CcSEcCtD
Sulindac—Insomnia—Epirubicin—testicular cancer	0.000177	0.000584	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—testicular cancer	0.000177	0.000583	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—testicular cancer	0.000176	0.00058	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—testicular cancer	0.000175	0.000578	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—testicular cancer	0.000174	0.000576	CcSEcCtD
Sulindac—Somnolence—Epirubicin—testicular cancer	0.000174	0.000574	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—testicular cancer	0.000173	0.00057	CcSEcCtD
Sulindac—Feeling abnormal—Methotrexate—testicular cancer	0.000172	0.000569	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—testicular cancer	0.000172	0.000569	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—KITLG—testicular cancer	0.000172	0.00166	CbGpPWpGaD
Sulindac—Gastrointestinal pain—Methotrexate—testicular cancer	0.000171	0.000565	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—testicular cancer	0.00017	0.000562	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—testicular cancer	0.000169	0.000559	CcSEcCtD
Sulindac—Fatigue—Epirubicin—testicular cancer	0.000169	0.000557	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—FGFR3—testicular cancer	0.000168	0.00162	CbGpPWpGaD
Sulindac—Constipation—Epirubicin—testicular cancer	0.000167	0.000552	CcSEcCtD
Sulindac—MAPK3—Immune System—BCL10—testicular cancer	0.000166	0.0016	CbGpPWpGaD
Sulindac—Urticaria—Methotrexate—testicular cancer	0.000166	0.000548	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—testicular cancer	0.000165	0.000546	CcSEcCtD
Sulindac—MAPK3—Axon guidance—MMP2—testicular cancer	0.000165	0.00159	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000165	0.000545	CcSEcCtD
Sulindac—PPARD—Metabolism—STK11—testicular cancer	0.000164	0.00158	CbGpPWpGaD
Sulindac—Insomnia—Doxorubicin—testicular cancer	0.000164	0.000541	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—testicular cancer	0.000163	0.000537	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—testicular cancer	0.000161	0.000533	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—testicular cancer	0.000161	0.000532	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—testicular cancer	0.000161	0.000531	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—testicular cancer	0.00016	0.000528	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—testicular cancer	0.000159	0.000526	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—testicular cancer	0.000157	0.00052	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—testicular cancer	0.000156	0.000515	CcSEcCtD
Sulindac—Urticaria—Epirubicin—testicular cancer	0.000155	0.000513	CcSEcCtD
Sulindac—Constipation—Doxorubicin—testicular cancer	0.000155	0.000511	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—testicular cancer	0.000155	0.000511	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—KIT—testicular cancer	0.000154	0.00149	CbGpPWpGaD
Sulindac—Hypersensitivity—Methotrexate—testicular cancer	0.000154	0.000509	CcSEcCtD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000154	0.00148	CbGpPWpGaD
Sulindac—Asthenia—Methotrexate—testicular cancer	0.00015	0.000495	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—testicular cancer	0.000149	0.000493	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000148	0.000489	CcSEcCtD
Sulindac—Pruritus—Methotrexate—testicular cancer	0.000148	0.000488	CcSEcCtD
Sulindac—Hypersensitivity—Epirubicin—testicular cancer	0.000144	0.000476	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—testicular cancer	0.000144	0.000475	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—testicular cancer	0.000143	0.000473	CcSEcCtD
Sulindac—Diarrhoea—Methotrexate—testicular cancer	0.000143	0.000472	CcSEcCtD
Sulindac—Asthenia—Epirubicin—testicular cancer	0.00014	0.000464	CcSEcCtD
Sulindac—Pruritus—Epirubicin—testicular cancer	0.000138	0.000457	CcSEcCtD
Sulindac—Dizziness—Methotrexate—testicular cancer	0.000138	0.000457	CcSEcCtD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000137	0.00132	CbGpPWpGaD
Sulindac—Diarrhoea—Epirubicin—testicular cancer	0.000134	0.000442	CcSEcCtD
Sulindac—Hypersensitivity—Doxorubicin—testicular cancer	0.000133	0.00044	CcSEcCtD
Sulindac—Vomiting—Methotrexate—testicular cancer	0.000133	0.000439	CcSEcCtD
Sulindac—Rash—Methotrexate—testicular cancer	0.000132	0.000435	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—testicular cancer	0.000132	0.000435	CcSEcCtD
Sulindac—Headache—Methotrexate—testicular cancer	0.000131	0.000432	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—testicular cancer	0.00013	0.000429	CcSEcCtD
Sulindac—Dizziness—Epirubicin—testicular cancer	0.000129	0.000427	CcSEcCtD
Sulindac—Pruritus—Doxorubicin—testicular cancer	0.000128	0.000423	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—FGFR3—testicular cancer	0.000128	0.00123	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000125	0.0012	CbGpPWpGaD
Sulindac—Vomiting—Epirubicin—testicular cancer	0.000124	0.000411	CcSEcCtD
Sulindac—Nausea—Methotrexate—testicular cancer	0.000124	0.00041	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—testicular cancer	0.000124	0.000409	CcSEcCtD
Sulindac—Rash—Epirubicin—testicular cancer	0.000123	0.000407	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—testicular cancer	0.000123	0.000407	CcSEcCtD
Sulindac—Headache—Epirubicin—testicular cancer	0.000123	0.000405	CcSEcCtD
Sulindac—Dizziness—Doxorubicin—testicular cancer	0.00012	0.000395	CcSEcCtD
Sulindac—MAPK3—Developmental Biology—MMP2—testicular cancer	0.000118	0.00114	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KIT—testicular cancer	0.000117	0.00113	CbGpPWpGaD
Sulindac—Nausea—Epirubicin—testicular cancer	0.000116	0.000384	CcSEcCtD
Sulindac—Vomiting—Doxorubicin—testicular cancer	0.000115	0.00038	CcSEcCtD
Sulindac—Rash—Doxorubicin—testicular cancer	0.000114	0.000377	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—testicular cancer	0.000114	0.000377	CcSEcCtD
Sulindac—Headache—Doxorubicin—testicular cancer	0.000113	0.000374	CcSEcCtD
Sulindac—MAPK3—Gene Expression—H2AFZ—testicular cancer	0.000108	0.00104	CbGpPWpGaD
Sulindac—Nausea—Doxorubicin—testicular cancer	0.000108	0.000355	CcSEcCtD
Sulindac—MAPK3—Disease—H2AFZ—testicular cancer	0.000101	0.00097	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KITLG—testicular cancer	0.0001	0.000967	CbGpPWpGaD
Sulindac—MAPK3—Disease—KITLG—testicular cancer	9.26e-05	0.000892	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.72e-05	0.00084	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—HPGDS—testicular cancer	8.64e-05	0.000833	CbGpPWpGaD
Sulindac—MAPK3—Immune System—FGFR3—testicular cancer	7.45e-05	0.000718	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—H2AFZ—testicular cancer	7.05e-05	0.000679	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STK11—testicular cancer	7.01e-05	0.000675	CbGpPWpGaD
Sulindac—MAPK3—Disease—FGFR3—testicular cancer	6.88e-05	0.000663	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HPGDS—testicular cancer	6.86e-05	0.000661	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KIT—testicular cancer	6.84e-05	0.00066	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KITLG—testicular cancer	6.48e-05	0.000625	CbGpPWpGaD
Sulindac—MAPK3—Disease—KIT—testicular cancer	6.32e-05	0.000609	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—STK11—testicular cancer	6.28e-05	0.000605	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HPGDS—testicular cancer	6.09e-05	0.000587	CbGpPWpGaD
Sulindac—PTGS2—Disease—H2AFZ—testicular cancer	5.99e-05	0.000577	CbGpPWpGaD
Sulindac—ALB—Metabolism—HPGDS—testicular cancer	5.55e-05	0.000535	CbGpPWpGaD
Sulindac—PTGS2—Disease—KITLG—testicular cancer	5.51e-05	0.000531	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—STK11—testicular cancer	4.98e-05	0.00048	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FGFR3—testicular cancer	4.82e-05	0.000464	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KIT—testicular cancer	4.42e-05	0.000426	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—STK11—testicular cancer	4.42e-05	0.000426	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGFR3—testicular cancer	4.09e-05	0.000394	CbGpPWpGaD
Sulindac—ALB—Metabolism—STK11—testicular cancer	4.03e-05	0.000389	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HPGDS—testicular cancer	3.88e-05	0.000374	CbGpPWpGaD
Sulindac—PTGS2—Disease—KIT—testicular cancer	3.76e-05	0.000362	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—STK11—testicular cancer	2.82e-05	0.000272	CbGpPWpGaD
